Allogene’s Cema-Cel Goes Express As Company Shifts To First-Line LBCL

Autoimmune CAR-T Could Sidestep Lymphodepletion

 
• By Alaric DeArment
  
Allogene announced a pivot to frontline consolidation of LBCL for its lead CAR-T candidate • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business